The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Effect of Screening on Ovarian Cancer Mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial
Abstract
CONTEXT: Screening for ovarian cancer with cancer antigen 125 (CA-125) and transvaginal ultrasound has an unknown effect on mortality. OBJECTIVE: To evaluate the effect of screening for ovarian cancer on mortality in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. DESIGN, SETTING, AND PARTICIPANTS: Randomized controlled trial of 78,216 women aged 55 to 74 years assigned to undergo either annual screening (n = 39,105) or usual care (n = 39,111) at 10 screening centers across the United States between November 1993 and July 2001. Intervention The intervention group was offered annual screening with CA-125 for 6 years and transvaginal ultrasound for 4 years. Participants and their health care practitioners received the screening test results and managed evaluation of abnormal results. The usual care group was not offered annual screening with CA-125 for 6 years or transvaginal ultrasound but received their usual medical care. Participants were followed up for a maximum of 13 years (median [range], 12.4 years [10.9-13.0 years]) for cancer diagnoses and death until February 28, 2010. MAIN OUTCOME MEASURES: Mortality from ovarian cancer, including primary peritoneal and fallopian tube cancers. Secondary outcomes included ovarian cancer incidence and complications associated with screening examinations and diagnostic procedures. RESULTS: Ovarian cancer was diagnosed in 212 women (5.7 per 10,000 person-years) in the intervention group and 176 (4.7 per 10,000 person-years) in the usual care group (rate ratio [RR], 1.21; 95% confidence interval [CI], 0.99-1.48). There were 118 deaths caused by ovarian cancer (3.1 per 10,000 person-years) in the intervention group and 100 deaths (2.6 per 10,000 person-years) in the usual care group (mortality RR, 1.18; 95% CI, 0.82-1.71). Of 3285 women with false-positive results, 1080 underwent surgical follow-up; of whom, 163 women experienced at least 1 serious complication (15%). There were 2924 deaths due to other causes (excluding ovarian, colorectal, and lung cancer) (76.6 per 10,000 person-years) in the intervention group and 2914 deaths (76.2 per 10,000 person-years) in the usual care group (RR, 1.01; 95% CI, 0.96-1.06). CONCLUSIONS: Among women in the general US population, simultaneous screening with CA-125 and transvaginal ultrasound compared with usual care did not reduce ovarian cancer mortality. Diagnostic evaluation following a false-positive screening test result was associated with complications. Trial Registration clinicaltrials.gov Identifier: NCT00002540.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Ten-Year Risk of False Positive Screening Mammograms and Clinical Breast Examinations
Elmore, J. G., Barton, M. B., Moceri, V. M., Polk, S., Arena, P. J., & Fletcher, S. W. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804163381601 · Cited by 1,053
Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial
Prorok, P. C., Andriole, G. L., Bresalier, R. S., Buys, S. S., Chia, D., David Crawford, E., Fogel, R., Gelmann, E. P., Gilbert, F., Hasson, M. A., et al. (2000) · Controlled Clinical Trials · doi:10.1016/s0197-2456(00)00098-2 · Cited by 1,037
Self-citationMenon, U., Gentry-Maharaj, A., Hallett, R., Ryan, A., Burnell, M., Sharma, A., Lewis, S., Davies, S., Philpott, S., Lopes, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70026-9 · Cited by 829
Screening for ovarian cancer: a pilot randomised controlled trial
Jacobs, I. J., Skates, S. J., MacDonald, N., Menon, U., Rosenthal, A. N., Davies, A. P., Woolas, R., Jeyarajah, A. R., Sibley, K., Lowe, D. G., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10261-1 · Cited by 560
Gohagan, J. K., Prorok, P. C., Hayes, R. B., & Kramer, B.-S. (2000) · Controlled Clinical Trials · doi:10.1016/s0197-2456(00)00097-0 · Cited by 544
Buys, S. S., Partridge, E., Greene, M. H., Prorok, P. C., Reding, D., Riley, T. L., Hartge, P., Fagerstrom, R. M., Ragard, L. R., Chia, D., et al. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.05.005 · Cited by 346
Self-citationA randomized study of screening for ovarian cancer: a multicenter study in Japan
KOBAYASHI, H., YAMADA, Y., SADO, T., SAKATA, M., YOSHIDA, S., KAWAGUCHI, R., KANAYAMA, S., SHIGETOMI, H., HARUTA, S., TSUJI, Y., et al. (2008) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.01035.x · Cited by 276
Results From Four Rounds of Ovarian Cancer Screening in a Randomized Trial
Partridge, E., Kreimer, A. R., Greenlee, R. T., Williams, C., Xu, J.-L., Church, T. R., Kessel, B., Johnson, C. C., Weissfeld, J. L., Isaacs, C., et al. (2009) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31819cda77 · Cited by 258
Self-citationSkates, S. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.955 · Cited by 256
The Preclinical Natural History of Serous Ovarian Cancer: Defining the Target for Early Detection
Brown, P. O., & Palmer, C. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000114 · Cited by 246
Prospective Study Using the Risk of Ovarian Cancer Algorithm to Screen for Ovarian Cancer
Menon, U., Skates, S. J., Lewis, S., Rosenthal, A. N., Rufford, B., Sibley, K., MacDonald, N., Dawnay, A., Jeyarajah, A., Bast, R. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.6642 · Cited by 243
Statistical Monitoring of Clinical Trials
Proschan, M. A., Lan, K. G., & Wittes, J. T. (2006) · Springer eBooks · doi:10.1007/978-0-387-44970-8 · Cited by 201
Statistical Monitoring of Clinical Trials: a Unified Approach
Chernick, M. R. (2007) · Technometrics · doi:10.1198/tech.2007.s479 · Cited by 186
Hayes, R. B., Reding, D., Kopp, W., Subar, A. F., Bhat, N., Rothman, N., Caporaso, N., Ziegler, R. G., Johnson, C. C., Weissfeld, J. L., et al. (2000) · Controlled Clinical Trials · doi:10.1016/s0197-2456(00)00101-x · Cited by 170
Biostatistics for Epidemiologists
Ziegel, E. R., & Ahlbom, A. (1995) · Technometrics · doi:10.2307/1269943 · Cited by 85
TEN-YEAR RISK OF FALSE POSITIVE SCREENING MAMMOGRAMS AND CLINICAL BREAST EXAMINATIONS
Pril, A., Oann, J., Lmore, G. E., Arton, M. A. B. B., Oceri, M. M., Olk, S. A. P., Rena, P. H. J. A., & Letcher, S. U. W. F. (2011) · Cited by 73
Black participation in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial
Stallings, F. L., Ford, M. E., Simpson, N. K., Fouad, M. N., Jernigan, J. C., Trauth, J. M., & Miller, D. S. (2000) · Controlled Clinical Trials · doi:10.1016/s0197-2456(00)00093-3 · Cited by 58
Biostatistics for Epidemiologists
Ahlbom, A. (2017) · CRC Press eBooks · doi:10.1201/9781315138411 · Cited by 41
A Randomized Study of Screening for Ovarian Cancer: A Multicenter Study in Japan
Kobayashi, H., Yamada, Y., Sado, T., Sakata, M., Yoshida, S., Kawaguchi, R., Kanayama, S., Shigetomi, H., Haruta, S., Tsuji, Y., et al. (2008) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000333238.05419.56 · Cited by 29
Results from Four Rounds of Ovarian Cancer Screening in a Randomized Trial
Partridge, E. E., Kreimer, A. R., Greenlee, R. T., Williams, C., Xu, J., Church, T. R., Kessel, B., Johnson, C. C., Weissfeld, J. L., Isaacs, C. J., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000358019.86136.11 · Cited by 19
Self-citation
Cited by
Jayson, G. C., Kohn, E. C., Kitchener, H. C., & Ledermann, J. A. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62146-7 · Cited by 1,850
Rethinking ovarian cancer: recommendations for improving outcomes
Vaughan, S., Coward, J. I., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. C., Drapkin, R., Etemadmoghadam, D., et al. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3144 · Cited by 1,464
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Bowtell, D. D., Böhm, S., Ahmed, A. A., Aspuria, P.-J., Bast, R. C., Beral, V., Berek, J. S., Birrer, M. J., Blagden, S., Bookman, M. A., et al. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4019 · Cited by 1,367
Matulonis, U. A., Sood, A. K., Fallowfield, L., Howitt, B. E., Sehouli, J., & Karlan, B. Y. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.61 · Cited by 1,362
Lin, J. S., Bowles, E. J. A., Williams, S. B., & Morrison, C. C. (2017) · JAMA · doi:10.1001/jama.2017.0562 · Cited by 1,082
Metadata
- Authors
- Buys, S. S.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2011-06-08
- Volume
- 305
- Issue
- 22
- Pages
- 2295
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2128104740
- Cited by
- 1,323
- References
- 22
- FWCI
- 104.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.